17-Jul-2026
Entera Bio Expands Share Authorization and Equity Plans
TipRanks (Fri, 17-Jul 5:15 AM ET)
TipRanks (Wed, 15-Jul 9:00 AM ET)
Market Chameleon (Tue, 23-Jun 7:44 AM ET)
Globe Newswire (Tue, 23-Jun 8:50 AM ET)
Market Chameleon (Mon, 22-Jun 7:45 AM ET)
Globe Newswire (Mon, 22-Jun 8:30 AM ET)
Globe Newswire (Tue, 16-Jun 8:33 AM ET)
Globe Newswire (Mon, 15-Jun 8:45 AM ET)
Globe Newswire (Thu, 28-May 8:50 AM ET)
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
Globe Newswire (Fri, 8-May 4:05 PM ET)
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
Entera Bio Ltd. - trades on the NASDAQ stock market under the symbol ENTX.
As of July 17, 2026, ENTX stock price declined to $1.98 with 241,955 million shares trading.
ENTX has a beta of -0.96, meaning it tends to be less sensitive to market movements. ENTX has a correlation of 0.02 to the broad based SPY ETF.
ENTX has a market cap of $97.47 million. This is considered a Micro Cap stock.
In the last 3 years, ENTX traded as high as $3.35 and as low as $.52.
ENTX has underperformed the market in the last year with a return of -2.9%, while SPY returned +20.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ENTX shares. However, ENTX has outperformed the market in the last 3 month and 2 week periods, returning +65.0% and +19.3%, while SPY returned +6.2% and -0.2%, respectively. This indicates ENTX has been having a stronger performance recently.
ENTX support price is $1.85 and resistance is $2.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENTX shares will trade within this expected range on the day.
